|55 Kenosia Avenue
Danbury, CT 06810
Toll Free: 1.800.999.6673
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
Copyright 1989, 1993, 1995, 1996, 1999, 2003, 2004
Acute respiratory distress syndrome (ARDS) is a type of severe, acute lung dysfunction affecting all or most of both lungs that occurs as a result of illness or injury. Although it is sometimes called adult respiratory distress syndrome, it may also affect children. Major symptoms may include breathing difficulties (dyspnea), rapid breathing (tachypnea), excessively deep and rapid breathing (hyperventilation) and insufficient levels of oxygen in the circulating blood (hypoxemia). ARDS may develop in conjunction with widespread infection in the body (sepsis) or as a result of pneumonia, trauma, shock, severe burns, aspiration of food into the lung, multiple blood transfusions, and inhalation of toxic fumes, among other things. It usually develops within 24 to 48 hours after the original illness or injury and is considered a medical emergency. It may progress to involvement of other organs.
Typically, ARDS develops within 24 to 48 hours of the original illness or injury. It may become a life-threatening condition characterized by inflammation of the lungs, which may begin in one lung but eventually affects both, and resulting damage to the air sacs (alveoli) and surrounding small blood vessels. The damaged alveoli close down or fill up with fluid (lung edema), thereby losing their ability to oxygenate the blood and eliminate carbon dioxide. Patients experience increasingly severe respiratory distress, associated with decreasing oxygen levels in arterial blood and tissues.
With the fluid buildup, the lungs become heavy, stiff, and unable to expand properly. Most patients require mechanical ventilation because of respiratory failure. The disorder may also be accompanied or followed by impairment of other vital functions, including cardiovascular, renal, hepatic, hematologic, and neurologic functions. Involvement of other organs in addition to the lungs may lead to a condition sometimes called multi-organ dysfunction syndrome.
The person with ARDS may initially appear agitated as a result of breathing difficulty, but later may become lethargic and or even comatose. He may appear pale, and the hands and feet may have a bluish-gray tone because of the diminished level of oxygen in the blood.
Risk factors for developing acute respiratory distress syndrome include infection in the body (sepsis), pneumonia, extensive trauma, severe low blood pressure (shock), severe burns, aspiration of food into the lung, inflammation of the pancreas, and multiple emergency blood transfusions. The disorder may also follow a near drowning or the inhalation of toxic fumes, or gases such as chlorine, phosgene, and nitrogen dioxide. Acute respiratory distress syndrome may affect people who have previously had healthy lungs, and it may affect children. It is not the same thing as infant respiratory distress syndrome, although the two share some similarities.
Acute respiratory distress syndrome can affect persons of any age who suffer acute injury or illness affecting the lungs. The incidence is believed to be between 1.5 and 4.8 per 100,000 of the population. Men and women appear to be equally affected.
Symptoms of the following disorders can be similar to those of acute respiratory distress syndrome. Comparisons may be useful for a differential diagnosis:
Severe acute respiratory syndrome (SARS) is a respiratory illness that began to be reported in Asia, North America and Europe in the spring of 2003. It begins with a fever greater than 100.4 degrees F. Other symptoms may include headache, an overall feeling of discomfort, body aches, and mild respiratory symptoms. After two to seven days, SARS patients may develop a dry, hacking cough and have trouble breathing. SARS appears to be spread by close person-to-person contact. For additional information on SARS, contact the Centers for Disease Control and Prevention or the World Health Organization.
Pneumonia is an infection of the lungs. Symptoms such as fever, cough, large amounts of mucous production (sputum), fluid in the space surrounding the lungs (pleurisy) and/or chills occur. Chest pain, headache, diarrhea, sore throat and fever blisters may also develop. Shortness of breath, difficulty in breathing, decreased exercise tolerance and night sweats are characteristic. Pneumonia frequently occurs in middle-aged to older adults with various underlying diseases. However, it can occur in persons of all ages, statistically most often in winter and early spring. Pneumonia can be caused by various bacteria, viruses, and other infectious agents.
Respiratory distress syndrome of the infant, also called hyaline membrane disease of the newborn, is characterized by respiratory distress seen especially in premature babies. A clear membrane is found lining the alveolar spaces in the lungs and is associated with reduced amounts of lung wetting agents or emulsifier (surfactant). The surfactant is a lipoprotein that stabilizes alveolar volume. When this surfactant is missing, the affected infant must be placed on some type of ventilator. (For more information on this disorder, choose "Respiratory Distress Syndrome, Infant" as your search term in the Rare Disease Database.)
The diagnosis is based on the presence of respiratory distress accompanied by low levels of oxygen in the blood and the presence of known risk factors such as sepsis, pneumonia, or trauma. Chest x-rays will show fluid filling spaces that should be filled with air. The presence of fluid in the air sacs and the "wet" breathing sounds sometimes made by patients may suggest congestive heart failure but a medical examination will distinguish between that condition and ARDS.
Standard therapy consists of mechanical ventilation, supplemental oxygen, and a technique called positive end expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury.
Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the course of the illness. Antibiotics are given to fight infection. Also, supportive treatment such as intravenous fluid or food may be needed. If other organ systems become involved, measures may be needed to support those organs.
The introduction into standard practice of a recent recommendation to use smaller "tidal volumes" (the volume of each individual breath delivered by the ventilator) has resulted in improved outcomes. Earlier, ventilators were set to deliver 12 ml per kg of body weight. Now only 6 ml per kg of body weight are delivered.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Steinbrook R. How best to ventilate? Trial design and patient safety in studies of the acute respiratory distress syndrome. N Eng J Med. 2003;348:1393-1401.
Said SI, Dickman KG. Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide. Reg Pept. 2000;93:21-29.
Bernard GR. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Eng J Med. 2000;344:699-709.
Tobin MJ. Culmination of an era in research on the actue respiratory distress syndrome. N Engl J Med. 2000;342:1360-61.
Ware LB, Marthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-39.
Hudson LD, et al. Protective ventilation for patients with acute respiratory distress syndrome. N Eng J Med. 1998;338:385-7.
Amato MBP, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Eng J Med. 1998;338:347-54.
Weg JG, et al. The relation of pneumothorax and other air leaks to mortality in the acute respiratory distress syndrome. N Eng J Med. 1998;338:341-6.
Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s: systemic inflammatory response and organ dysfunction. JAMA 1994;271:226-33.
Villar J, Slutsky AS. The incidence of the adult respiratory distress syndrome. Am Rev Respir Dis 1989;140:814-16.
Report last updated: 2008/05/14 00:00:00 GMT+0